{"id":"NCT00603993","sponsor":"Abbott","briefTitle":"Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","officialTitle":"A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2006-11","completion":null,"firstPosted":"2008-01-29","resultsPosted":"2010-02-04","lastUpdate":"2011-06-21"},"enrollment":88,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["Humira","ABT-D2E7"]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.","primaryOutcome":{"measure":"Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively)","timeFrame":"Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value)","effectByArm":[{"arm":"Adalimumab 40 mg or 80 mg Every Other Week (Eow)","deltaMin":66,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":88},"commonTop":["Nasopharyngitis","Adverse drug reaction","Antinuclear antibody positive","Constipation","Bronchitis"]}}